APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapies

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cancer Immunotherapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173974280320 December 2025192 pages

Choose your research edition.

Industry ResearchCancer Immunotherapies Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapies Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapies Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapies Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapies market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cancer Immunotherapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Immunotherapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Immunotherapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cancer Immunotherapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Immunotherapies include ARMO BioSciences (Eli Lilly), Bristol-Myers Squibb, Gilead Sciences, AstraZeneca, AbbVie, Amgen, Bayer, Pfizer and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Immunotherapies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Immunotherapies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Immunotherapies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Immunotherapies market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Immunotherapies Segment by Company

ARMO BioSciences (Eli Lilly)

Bristol-Myers Squibb

Gilead Sciences

AstraZeneca

AbbVie

Amgen

Bayer

Pfizer

Roche

Merck

Novartis

Johnson & Johnson

Cancer Immunotherapies Segment by Type

Immunomodulators

Checkpoint Inhibitors

Adoptive Cell transfer

Monoclonal Antibodies (MABs)

Cancer Vaccines

Cancer Immunotherapies Segment by Application

Breast Cancer

Lymphoma

Colorectal Cancer

Melanoma

Non-Small Cell Lung Cancer

Leukemia

Cancer Immunotherapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Immunotherapies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Immunotherapies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cancer Immunotherapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cancer Immunotherapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cancer Immunotherapies Industry Trends Table 2. Cancer Immunotherapies Industry Drivers Table 3. Cancer Immunotherapies Industry Opportunities and Challenges Table 4. Cancer Immunotherapies Industry Restraints Table 5. Global Cancer Immunotherapies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cancer Immunotherapies Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cancer Immunotherapies Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Cancer Immunotherapies Sales Market Share by Manufacturers Table 9. Global Cancer Immunotherapies Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Cancer Immunotherapies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cancer Immunotherapies Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cancer Immunotherapies Manufacturers, Product Type & Application Table 13. Global Cancer Immunotherapies Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Immunotherapies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Immunomodulators Table 17. Major Manufacturers of Checkpoint Inhibitors Table 18. Major Manufacturers of Adoptive Cell transfer Table 19. Major Manufacturers of Monoclonal Antibodies (MABs) Table 20. Major Manufacturers of Cancer Vaccines Table 21. Global Cancer Immunotherapies Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Cancer Immunotherapies Sales by Type (2021-2026) & (k units) Table 23. Global Cancer Immunotherapies Sales by Type (2027-2032) & (k units) Table 24. Global Cancer Immunotherapies Sales Market Share by Type (2021-2026) Table 25. Global Cancer Immunotherapies Sales Market Share by Type (2027-2032) Table 26. Global Cancer Immunotherapies Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Cancer Immunotherapies Revenue by Type (2021-2026) & (k units) Table 28. Global Cancer Immunotherapies Revenue by Type (2027-2032) & (k units) Table 29. Global Cancer Immunotherapies Revenue Market Share by Type (2021-2026) Table 30. Global Cancer Immunotherapies Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Breast Cancer Table 32. Major Manufacturers of Lymphoma Table 33. Major Manufacturers of Colorectal Cancer Table 34. Major Manufacturers of Melanoma Table 35. Major Manufacturers of Non-Small Cell Lung Cancer Table 36. Major Manufacturers of Leukemia Table 37. Global Cancer Immunotherapies Sales by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Cancer Immunotherapies Sales by Application (2021-2026) & (k units) Table 39. Global Cancer Immunotherapies Sales by Application (2027-2032) & (k units) Table 40. Global Cancer Immunotherapies Sales Market Share by Application (2021-2026) Table 41. Global Cancer Immunotherapies Sales Market Share by Application (2027-2032) Table 42. Global Cancer Immunotherapies Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 43. Global Cancer Immunotherapies Revenue by Application (2021-2026) & (k units) Table 44. Global Cancer Immunotherapies Revenue by Application (2027-2032) & (k units) Table 45. Global Cancer Immunotherapies Revenue Market Share by Application (2021-2026) Table 46. Global Cancer Immunotherapies Revenue Market Share by Application (2027-2032) Table 47. Global Cancer Immunotherapies Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Cancer Immunotherapies Sales by Region (2021-2026) & (k units) Table 49. Global Cancer Immunotherapies Sales Market Share by Region (2021-2026) Table 50. Global Cancer Immunotherapies Sales Forecasted by Region (2027-2032) & (k units) Table 51. Global Cancer Immunotherapies Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Cancer Immunotherapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. North America Cancer Immunotherapies Sales by Country (2021-2026) & (k units) Table 54. North America Cancer Immunotherapies Sales by Country (2027-2032) & (k units) Table 55. Europe Cancer Immunotherapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Europe Cancer Immunotherapies Sales by Country (2021-2026) & (k units) Table 57. Europe Cancer Immunotherapies Sales by Country (2027-2032) & (k units) Table 58. Asia Pacific Cancer Immunotherapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Asia Pacific Cancer Immunotherapies Sales by Country (2021-2026) & (k units) Table 60. Asia Pacific Cancer Immunotherapies Sales by Country (2027-2032) & (k units) Table 61. South America, Middle East and Africa Cancer Immunotherapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 62. South America, Middle East and Africa Cancer Immunotherapies Sales by Country (2021-2026) & (k units) Table 63. South America, Middle East and Africa Cancer Immunotherapies Sales by Country (2027-2032) & (k units) Table 64. Global Cancer Immunotherapies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Cancer Immunotherapies Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Cancer Immunotherapies Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Cancer Immunotherapies Revenue Market Share by Region (2021-2026) Table 68. Global Cancer Immunotherapies Revenue Market Share by Region (2027-2032) Table 69. ARMO BioSciences (Eli Lilly) Company Information Table 70. ARMO BioSciences (Eli Lilly) Business Overview Table 71. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolio Table 73. ARMO BioSciences (Eli Lilly) Recent Development Table 74. Bristol-Myers Squibb Company Information Table 75. Bristol-Myers Squibb Business Overview Table 76. Bristol-Myers Squibb Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bristol-Myers Squibb Cancer Immunotherapies Product Portfolio Table 78. Bristol-Myers Squibb Recent Development Table 79. Gilead Sciences Company Information Table 80. Gilead Sciences Business Overview Table 81. Gilead Sciences Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Gilead Sciences Cancer Immunotherapies Product Portfolio Table 83. Gilead Sciences Recent Development Table 84. AstraZeneca Company Information Table 85. AstraZeneca Business Overview Table 86. AstraZeneca Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. AstraZeneca Cancer Immunotherapies Product Portfolio Table 88. AstraZeneca Recent Development Table 89. AbbVie Company Information Table 90. AbbVie Business Overview Table 91. AbbVie Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. AbbVie Cancer Immunotherapies Product Portfolio Table 93. AbbVie Recent Development Table 94. Amgen Company Information Table 95. Amgen Business Overview Table 96. Amgen Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Amgen Cancer Immunotherapies Product Portfolio Table 98. Amgen Recent Development Table 99. Bayer Company Information Table 100. Bayer Business Overview Table 101. Bayer Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Bayer Cancer Immunotherapies Product Portfolio Table 103. Bayer Recent Development Table 104. Pfizer Company Information Table 105. Pfizer Business Overview Table 106. Pfizer Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Pfizer Cancer Immunotherapies Product Portfolio Table 108. Pfizer Recent Development Table 109. Roche Company Information Table 110. Roche Business Overview Table 111. Roche Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Roche Cancer Immunotherapies Product Portfolio Table 113. Roche Recent Development Table 114. Merck Company Information Table 115. Merck Business Overview Table 116. Merck Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Merck Cancer Immunotherapies Product Portfolio Table 118. Merck Recent Development Table 119. Novartis Company Information Table 120. Novartis Business Overview Table 121. Novartis Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Novartis Cancer Immunotherapies Product Portfolio Table 123. Novartis Recent Development Table 124. Johnson & Johnson Company Information Table 125. Johnson & Johnson Business Overview Table 126. Johnson & Johnson Cancer Immunotherapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Johnson & Johnson Cancer Immunotherapies Product Portfolio Table 128. Johnson & Johnson Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Cancer Immunotherapies Distributors List Table 132. Cancer Immunotherapies Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Cancer Immunotherapies Product Image Figure 2. Global Cancer Immunotherapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Immunotherapies Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Immunotherapies Sales (2021-2032) & (k units) Figure 5. Global Cancer Immunotherapies Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cancer Immunotherapies Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Immunomodulators Image Figure 9. Checkpoint Inhibitors Image Figure 10. Adoptive Cell transfer Image Figure 11. Monoclonal Antibodies (MABs) Image Figure 12. Cancer Vaccines Image Figure 13. Global Cancer Immunotherapies Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Cancer Immunotherapies Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Cancer Immunotherapies Sales Market Share by Type (2021-2032) Figure 16. Global Cancer Immunotherapies Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Cancer Immunotherapies Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Cancer Immunotherapies Revenue Market Share by Type (2021-2032) Figure 19. Breast Cancer Image Figure 20. Lymphoma Image Figure 21. Colorectal Cancer Image Figure 22. Melanoma Image Figure 23. Non-Small Cell Lung Cancer Image Figure 24. Leukemia Image Figure 25. Global Cancer Immunotherapies Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Cancer Immunotherapies Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Cancer Immunotherapies Sales Market Share by Application (2021-2032) Figure 28. Global Cancer Immunotherapies Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 29. Global Cancer Immunotherapies Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Cancer Immunotherapies Revenue Market Share by Application (2021-2032) Figure 31. North America Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 32. North America Cancer Immunotherapies Sales Market Share by Country (2021-2032) Figure 33. U.S. Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 34. Canada Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 35. Mexico Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 37. Europe Cancer Immunotherapies Sales Market Share by Country (2021-2032) Figure 38. Germany Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 39. France Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 40. U.K. Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 41. Italy Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 42. Netherlands Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 44. Asia Pacific Cancer Immunotherapies Sales Market Share by Country (2021-2032) Figure 45. China Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 46. Japan Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Korea Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 48. Southeast Asia Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 49. India Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 50. Australia Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 52. South America, Middle East and Africa Cancer Immunotherapies Sales Market Share by Country (2021-2032) Figure 53. Brazil Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 54. South Africa Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 55. Saudi Arabia Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 56. Turkey Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 57. Argentina Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 58. UAE Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 59. Egypt Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 60. Chile Cancer Immunotherapies Sales and Growth Rate (2021-2032) & (k units) Figure 61. Global Cancer Immunotherapies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Cancer Immunotherapies Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Cancer Immunotherapies Revenue (2021-2032) & (US$ Million) Figure 64. North America Cancer Immunotherapies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Cancer Immunotherapies Revenue (2021-2032) & (US$ Million) Figure 66. Europe Cancer Immunotherapies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Cancer Immunotherapies Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Cancer Immunotherapies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Cancer Immunotherapies Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Cancer Immunotherapies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Cancer Immunotherapies Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Cancer Immunotherapies Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Immunomodulators
  • Checkpoint Inhibitors
  • Adoptive Cell transfer
  • Monoclonal Antibodies (MABs)
  • Cancer Vaccines
Applications
  • Breast Cancer
  • Lymphoma
  • Colorectal Cancer
  • Melanoma
  • Non-Small Cell Lung Cancer
  • Leukemia
Companies covered
  • ARMO BioSciences (Eli Lilly)
  • Bristol-Myers Squibb
  • Gilead Sciences
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bayer
  • Pfizer
  • Roche
  • Merck
  • Novartis
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Immunotherapies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Immunotherapies Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cancer Immunotherapies Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cancer Immunotherapies Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cancer Immunotherapies Market Dynamics
  1. 2.1 Cancer Immunotherapies Industry Trends
  2. 2.2 Cancer Immunotherapies Industry Drivers
  3. 2.3 Cancer Immunotherapies Industry Opportunities and Challenges
  4. 2.4 Cancer Immunotherapies Industry Restraints
3 Cancer Immunotherapies Market by Manufacturers
  1. 3.1 Global Cancer Immunotherapies Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cancer Immunotherapies Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cancer Immunotherapies Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cancer Immunotherapies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Immunotherapies Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cancer Immunotherapies Manufacturers, Product Type & Application
  7. 3.7 Global Cancer Immunotherapies Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Immunotherapies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Immunotherapies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Immunotherapies Tier 1, Tier 2, and Tier 3
4 Cancer Immunotherapies Market by Type
  1. 4.1 Cancer Immunotherapies Type Introduction
  2. 4.1.1 Immunomodulators
  3. 4.1.2 Checkpoint Inhibitors
  4. 4.1.3 Adoptive Cell transfer
  5. 4.1.4 Monoclonal Antibodies (MABs)
  6. 4.1.5 Cancer Vaccines
  7. 4.2 Global Cancer Immunotherapies Sales by Type
  8. 4.2.1 Global Cancer Immunotherapies Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Cancer Immunotherapies Sales by Type (2021-2032)
  10. 4.2.3 Global Cancer Immunotherapies Sales Market Share by Type (2021-2032)
  11. 4.3 Global Cancer Immunotherapies Revenue by Type
  12. 4.3.1 Global Cancer Immunotherapies Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Cancer Immunotherapies Revenue by Type (2021-2032)
  14. 4.3.3 Global Cancer Immunotherapies Revenue Market Share by Type (2021-2032)
5 Cancer Immunotherapies Market by Application
  1. 5.1 Cancer Immunotherapies Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Lymphoma
  4. 5.1.3 Colorectal Cancer
  5. 5.1.4 Melanoma
  6. 5.1.5 Non-Small Cell Lung Cancer
  7. 5.1.6 Leukemia
  8. 5.2 Global Cancer Immunotherapies Sales by Application
  9. 5.2.1 Global Cancer Immunotherapies Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Cancer Immunotherapies Sales by Application (2021-2032)
  11. 5.2.3 Global Cancer Immunotherapies Sales Market Share by Application (2021-2032)
  12. 5.3 Global Cancer Immunotherapies Revenue by Application
  13. 5.3.1 Global Cancer Immunotherapies Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Cancer Immunotherapies Revenue by Application (2021-2032)
  15. 5.3.3 Global Cancer Immunotherapies Revenue Market Share by Application (2021-2032)
6 Global Cancer Immunotherapies Sales by Region
  1. 6.1 Global Cancer Immunotherapies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Immunotherapies Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Immunotherapies Sales by Region (2021-2026)
  4. 6.2.2 Global Cancer Immunotherapies Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Immunotherapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cancer Immunotherapies Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cancer Immunotherapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cancer Immunotherapies Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cancer Immunotherapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cancer Immunotherapies Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cancer Immunotherapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cancer Immunotherapies Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cancer Immunotherapies Revenue by Region
  1. 7.1 Global Cancer Immunotherapies Revenue by Region
  2. 7.1.1 Global Cancer Immunotherapies Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cancer Immunotherapies Revenue by Region (2021-2026)
  4. 7.1.3 Global Cancer Immunotherapies Revenue by Region (2027-2032)
  5. 7.1.4 Global Cancer Immunotherapies Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cancer Immunotherapies Revenue (2021-2032)
  8. 7.2.2 North America Cancer Immunotherapies Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cancer Immunotherapies Revenue (2021-2032)
  11. 7.3.2 Europe Cancer Immunotherapies Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cancer Immunotherapies Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cancer Immunotherapies Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cancer Immunotherapies Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cancer Immunotherapies Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 ARMO BioSciences (Eli Lilly)
  2. 8.1.1 ARMO BioSciences (Eli Lilly) Company Information
  3. 8.1.2 ARMO BioSciences (Eli Lilly) Business Overview
  4. 8.1.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolio
  6. 8.1.5 ARMO BioSciences (Eli Lilly) Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Cancer Immunotherapies Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Cancer Immunotherapies Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Cancer Immunotherapies Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 AbbVie
  26. 8.5.1 AbbVie Company Information
  27. 8.5.2 AbbVie Business Overview
  28. 8.5.3 AbbVie Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Cancer Immunotherapies Product Portfolio
  30. 8.5.5 AbbVie Recent Developments
  31. 8.6 Amgen
  32. 8.6.1 Amgen Company Information
  33. 8.6.2 Amgen Business Overview
  34. 8.6.3 Amgen Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Amgen Cancer Immunotherapies Product Portfolio
  36. 8.6.5 Amgen Recent Developments
  37. 8.7 Bayer
  38. 8.7.1 Bayer Company Information
  39. 8.7.2 Bayer Business Overview
  40. 8.7.3 Bayer Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bayer Cancer Immunotherapies Product Portfolio
  42. 8.7.5 Bayer Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Cancer Immunotherapies Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche Cancer Immunotherapies Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Merck
  56. 8.10.1 Merck Company Information
  57. 8.10.2 Merck Business Overview
  58. 8.10.3 Merck Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merck Cancer Immunotherapies Product Portfolio
  60. 8.10.5 Merck Recent Developments
  61. 8.11 Novartis
  62. 8.11.1 Novartis Company Information
  63. 8.11.2 Novartis Business Overview
  64. 8.11.3 Novartis Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Cancer Immunotherapies Product Portfolio
  66. 8.11.5 Novartis Recent Developments
  67. 8.12 Johnson & Johnson
  68. 8.12.1 Johnson & Johnson Company Information
  69. 8.12.2 Johnson & Johnson Business Overview
  70. 8.12.3 Johnson & Johnson Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Johnson & Johnson Cancer Immunotherapies Product Portfolio
  72. 8.12.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Immunotherapies Value Chain Analysis
  2. 9.1.1 Cancer Immunotherapies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Immunotherapies Production Mode & Process
  6. 9.2 Cancer Immunotherapies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Immunotherapies Distributors
  9. 9.2.3 Cancer Immunotherapies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst